Q1 FY27 earnings call · August 15, 2026

Ipca Laboratories Ltd (IPCALAB) Q1 FY27 Earnings Call: Guides 14-16% Revenue Growth, Consolidated EBITDA Margin Expands 449 bps

Cofacto ResearchPublished August 15, 20266 min read
Quick summary

Ipca Laboratories Ltd held its Q1 FY27 earnings call on August 13, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Broad-Based Growth With Material Margin Expansion

  • Consolidated revenue of Rs.2,788 Cr — up 21% YoY in Q1 FY 2026-2027, driven by strong export and domestic formulation performance.
  • Consolidated EBITDA margin of 22.88% — expanded 449 bps from 18.39% in Q1 FY 2025-2026; absolute EBITDA rose ~50% YoY to Rs.638 Cr.
  • Standalone EBITDA margin reached 26% — up from 23.82% in the prior-year quarter, with absolute EBITDA of Rs.557 Cr (+~34% YoY).
  • Domestic formulation revenue of Rs.1,082 Cr — up 13% YoY from Rs.961 Cr in Q1 FY 2025-2026; IQVIA rank held at ~16 with market share of 2.08% (vs. 2.07% in March 2026).
  • Total export revenue of Rs.603 Cr — up 34% YoY, powered by branded ROW (+16%), generic ex-tender (+27%), and institutional generics (+107% YoY, partially boosted by ~Rs.40 Cr of March shipments deferred to April).
  • API business grew 30% YoY — reaching Rs.424 Cr in Q1 FY 2026-2027 from Rs.362 Cr in Q1 FY 2025-2026.

Chronic Outperformance and Therapy-Area Breadth

  • India business grew 8.9% (IQVIA) — vs. IPM growth of 6.5% in Q1 FY 2026-2027; the chronic segment advanced 15.2%, in line with the market.
  • Volume growth of ~5%, price growth of ~4.5-5% — and new product launches contributed ~2% to the overall domestic growth of ~13% in Q1 FY 2026-2027.
  • Analyst Kartik Banne noted — Ipca's volume growth is higher than the industry, a positive structural signal for market share gains.
  • Therapy-area growth was broad-based — cardiovascular/diabetes +17%, CNS +19%, dermatology +17%, urology +25%, ophthalmology +17%, and pain management +13% in Q1 FY 2026-2027.
  • Anti-malarial segment declined ~24% — now only ~1% of the overall business, reducing drag on the portfolio.
  • Chronic segment grew 17.2%, acute grew 8.9% — both outperforming the Indian Pharmaceutical Market (IPM) growth of 11.7% as measured by IQVIA.

EU Surge and US Momentum Reinforce Export Trajectory

  • Generic business ex-institutions surged — from Rs.268 Cr to Rs.370 Cr in Q1 FY 2026-2027; EU business jumped from Rs.23 Cr to Rs.137 Cr, driven by new launches and market share gains.
  • US business grew 8% in Q1 FY 2026-2027 — management guided ~15-17% revenue growth in the US over the next 1-2 years (FY 2026-2027 to FY 2027-2028), with 3-4 Ipca and 3-4 Unichem product launches per year (total ~7-8).
  • Institutional business run-rate of Rs.260-300 Cr per year — expected to remain low single-digit growth for FY 2026-2027; one-off ~Rs.40 Cr shipment delayed from March to April boosted Q1 comparables.
  • Brazil grew 52% — Akesia doubled from Rs.8 Cr to Rs.17 Cr in Q1 FY 2026-2027, reflecting expanding geographic reach.
  • Branded ROW revenue of Rs.143 Cr — up 16% YoY, with generic ex-tender at Rs.340 Cr (+27%) and institutional generic at Rs.111.75 Cr (+107% YoY).
  • Canada declined slightly — partially offsetting strong growth in other export markets; management did not quantify the decline.

Structural Margin Improvement Faces Freight Headwinds

  • Standalone EBITDA margin improved ~2.4% YoY — driven by personal cost (-1.41% of sales) and manufacturing cost (-0.91%); material cost savings were only 0.14% in Q1 FY 2026-2027.
  • Consolidated EBITDA margin expanded 4.49% YoY — to 22.88% in Q1 FY 2026-2027, aided by cost reductions, captive API production, and a stronger European business mix.
  • Freight rates have increased 3x on key routes — US container rates rose from $7,000-7,500 to $12,500-13,000; management flagged that these are baked into guidance despite worsening conditions from July to August 2026.
  • Management stated no renegotiation of dollar prices — contrary to analyst expectations, prices are increasing due to rising costs, and the rupee depreciation benefit will not be negotiated away.
  • Raw material cost to sales is approximately 25% — rupee depreciation provides a net margin benefit by increasing some dollar-linked costs while Indian costs remain stable.
  • Interest cost expected to decline further — total debt of Rs.193 Cr (long-term only, no working capital debt); a Rs.70 Cr term loan will be repaid by end of FY 2026-2027; cash on books exceeds total debt.

Upgraded Targets, Biotech Build-Out and Capex Ramp

  • Revenue guidance for FY 2026-2027 raised to 14-16% — revised up from 12-13%, driven by the generic business (particularly EU), India performance, and API.
  • Consolidated EBITDA margin guidance raised to 23% — for FY 2026-2027, up from 22%, citing better-than-expected performance in Q1.
  • FY 2027-2028 guidance deferred to Q4 FY 2026-2027 — management indicated that the next fiscal year's outlook will be provided at the time of Q4 FY 2026-2027 results.
  • Total capex of Rs.700-800 Cr guided for FY 2026-2027 — directed at capacity expansion for European and US formulations (controlled/extended release), biotech R&D, new API plants at Dewas and Wardha, and intermediate-to-continuous process conversions.
  • Biotech investment of ~Rs.100 Cr in FY 2026-2027 — expanding piloting facilities and R&D 7 biosimilar candidates in pipeline, with 2 advanced products in validation stage.
  • Biosimilar revenue expected from FY 2028-2029 / FY 2029-2030 — management stated "biosimilar revenue is expected to start flowing from FY2028-2029 / FY2029-2030", with first filings targeted in FY 2027-2028 and clinical trials beginning in the same period.
  • Phase 3 clinical trial waivers obtained from European and US regulators — reducing clinical development costs and timelines; one biosimilar targets near-patent expiry while remainder are off-patent with yields double or more of current market standards.

Unichem on Track, Lyka Labs Turnaround Underway

  • Unichem revenue grew ~21% in Q1 FY 2026-2027 — including ~5% contribution from rupee depreciation (rupee depreciated ~11% YoY against the dollar).
  • Unichem EBITDA margin could improve from ~26% to ~30% — over the medium term, management guided; consolidated EBITDA margin may settle at ~25-26% in 2-3 years (by ~FY 2028-2029).
  • Unichem's FY 2026-2027 guidance unchanged at 10% revenue growth and 13% EBITDA margin — under review, not yet revised; margin improvement driven by cost reductions, captive API, stronger European business, and Brazil turning profitable.
  • Unichem total US portfolio grew 27% — its own portfolio grew 9%; Unichem's API grew 73% to ~Rs.58 Cr; new product filings underway in Europe, Australia, New Zealand, Canada, Chile, and other markets.
  • Lyka Labs (associate) has not grown revenue and reported negative EBITDA — invested via primary route from FY22 to FY25; three business pillars under construction: animal health injectables, direct hospital sales in critical care, and IVF products.
  • Lyka added a significant field force over the last two years — incurring costs that keep some divisions below breakeven; management is hopeful of a turnaround. Analyst Mohit requested Lyka Labs issue press releases on progress, citing difficulty in tracking the listed associate's performance.

Ask about this

Ask Cofacto a question about this call. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This earnings call summary is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.